Posted inClinical Updates Wellness & Lifestyle
Rapid Initial Benefits of Secukinumab in Early Psoriatic Arthritis: Insights from a Treat-to-Target Randomized Trial
Early secukinumab use in newly diagnosed psoriatic arthritis delivers faster clinical improvement at 3 months compared to standard care, but this advantage diminishes by 6 months and beyond.